Kidney Disease and COVID-19 Disease Severity-Systematic Review and Meta-Analysis

Authors

Jagmeet Singh, Geisinger Commonwealth School of Medicine, Scranton, PA, USA.
Preeti Malik, Department of Public Health, Icahn School of Medicine At Mount Sinai, 1 Gustave L. Levy Pl, New York, NY, USA. pmalik.ma@gmail.com.
Nidhi Patel, Drexel University College of Medicine, Philadelphia, PA, USA.Follow
Suveenkrishna Pothuru, Ascension Via Christi Hospital, Manhattan, KS, USA.
Avantika Israni, St Mary Medical Center, Langhorne, PA, USA.
Raja Chandra Chakinala, Guthrie Robert Packer Hospital, Sayre, PA, USA.
Maryam Rafaqat Hussain, Department of Public Health, Icahn School of Medicine At Mount Sinai, 1 Gustave L. Levy Pl, New York, NY, USA.
Anusha Chidharla, University of Illinois College of Medicine Peoria, Champaign, IL, USA.
Harshil Patel, Ascension Providence Hospital/Michigan State University College of Human Medicine, East Lansing, USA.
Saurabh Kumar Patel, University of Illinois at Chicago, Chicago, IL, USA.
Rizwan Rabbani, Temple University, Philadelphia, PA, USA.
Urvish Patel, Department of Public Health, Icahn School of Medicine At Mount Sinai, 1 Gustave L. Levy Pl, New York, NY, USA.Follow
Savneek Chugh, New York Medical College, Hawthorne, NY, USA.
Asim Kichloo, College of Medicine, Central Michigan University, Saginaw, MI, USA.

Author Type(s)

Faculty

DOI

10.1007/s10238-021-00715-x

Journal Title

Clinical and Experimental Medicine

First Page

125

Last Page

135

Document Type

Article

Publication Date

2-1-2022

Department

Medicine

Abstract

We aimed to identify prevalence and association of comorbid chronic kidney disease (CKD), acute kidney injury (AKI) and utilization prevalence of continuous renal replacement therapy (CRRT) in COVID-19-hospitalized patients as a function of severity status. With the ongoing struggle across the globe to combat COVID-19 disease, published literature has described the role of kidney disease in COVID-19 patients based on single/multicenter experiences across the globe. We extracted data from observational studies describing comorbid CKD, AKI and CRRT and outcomes and severity of COVID-19-hospitalized patients from December 1, 2019-August 20, 2020 following PRISMA guidelines. Severity of COVID-19 includes intensive care unit admission, oxygen saturation < 90%, invasive mechanical ventilation utilization, in-hospital admission and mortality. Meta-analysis was performed using a random-effects model to calculate pooled estimates, and forest plots were created. In total, 29 studies with 15,017 confirmed COVID-19 patients were included. The overall prevalence of AKI was 11.6% [(430/3693)], comorbid CKD 9.7% [(1342/13,728)] and CRRT 2.58% [(102/3946)] in our meta-analysis. We also found higher odds of comorbid CKD (pooled OR: 1.70; 95%CI: 1.21-2.40; p = 0.002), AKI (8.28; 4.42-15.52; p < 0.00001) and utilization of CRRT (16.90; 9.00-31.74; p < 0.00001) in patients with severe COVID-19 disease. Conclusion Our meta-analysis suggests that comorbid CKD, AKI and utilization of CRRT were significantly associated with COVID-19 disease severity. Clinicians should focus on early triaging of COVID-19 patients with comorbid CKD and at risk for AKI to prevent complication and mortality.

Recommended Citation

Singh, J., Malik, P., Patel, N., Pothuru, S., Israni, A., Chakinala, R. C., Hussain, M. R., Chidharla, A., Patel, H., Patel, S. K., Rabbani, R., Patel, U., Chugh, S., & Kichloo, A. (2022). Kidney Disease and COVID-19 Disease Severity-Systematic Review and Meta-Analysis. Clinical and Experimental Medicine, 22 (1), 125-135. https://doi.org/10.1007/s10238-021-00715-x